This is a routine regulatory policy change with minimal constitutional implications. The FDA streamlining approval processes for biosimilars is standard administrative action within existing statutory authority (Biologics Price Competition and Innovation Act). Rule_of_law scores 1 for minor procedural adjustment; capture scores 2 as pharmaceutical industry may benefit from reduced barriers, though this also serves public interest in drug affordability. No election interference, separation of powers issues, civil rights impacts, corruption indicators, or violence. Severity multipliers near baseline as this is reversible administrative policy. B-score is low: minimal outrage potential, moderate novelty for healthcare policy watchers, some media interest in drug pricing context but limited viral potential. No strategic distraction indicators. Both A-score (3.11) and B-score (2.75) fall well below thresholds of 25. This is routine administrative governance with potential positive public health implications.